Profile data is unavailable for this security.
About the company
Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. Its focus is on the therapeutic areas of hematology-oncology and allergy, dermatology, and rheumatology. It operates through two product portfolios: Medexus Pharma Canada and Medexus Pharma. Its lead products are IXINITY (US), GRAFAPEX (US), Trecondyv (Canada), Rupall (Canada), Rasuvo (US), Metoject (Canada), and Gleolan (US). IXINITY (US) is an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B. Rupall (Canada) is a prescription allergy medication with a mode of action. Rasuvo (US) and Metoject (Canada) is a formulation of methotrexate designed to treat rheumatoid arthritis and other autoimmune diseases. Gleolan (US) is an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
- Revenue in CAD (TTM)142.72m
- Net income in CAD522.35k
- Incorporated2021
- Employees91.00
- LocationMedexus Pharmaceuticals Inc10 King Street East, Suite 600TORONTO M5C 1C3CanadaCAN
- Phone+1 (514) 762-2626
- Websitehttps://www.medexus.com/en_US
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Decibel Cannabis Company Inc | 109.31m | 12.32m | 51.93m | -- | 3.41 | 0.8166 | 2.68 | 0.4751 | 0.0264 | 0.025 | 0.198 | 0.1102 | 0.795 | 2.15 | 6.51 | -- | 8.96 | -0.0401 | 13.94 | -0.0595 | 21.98 | 20.03 | 11.27 | -0.0688 | 0.6086 | -5.57 | 0.4186 | -- | -12.89 | 71.51 | 810.61 | -- | -4.74 | -- |
| Arch Biopartners Inc | 275.95k | -1.55m | 54.22m | -- | -- | -- | -- | 196.47 | -0.0237 | -0.0237 | 0.0042 | -0.0587 | 0.5306 | -- | 0.7616 | -- | -298.56 | -195.50 | -- | -- | -- | -- | -562.69 | -123.23 | -- | -3.99 | -- | -- | -87.00 | 32.37 | 60.39 | -- | -- | -- |
| Eastwood Bio-Medical Canada Inc | 594.57k | -411.84k | 59.24m | -- | -- | -- | -- | 99.64 | -0.006 | -0.006 | 0.0086 | -0.0225 | 2.17 | -- | 26.00 | -- | -150.26 | -71.29 | -- | -- | 63.91 | 56.40 | -69.27 | -57.09 | -- | -31.24 | -- | -- | -19.11 | -11.50 | 16.60 | -- | -- | -- |
| LSL Pharma Group Inc | 26.80m | 2.78m | 63.36m | -- | 20.82 | 2.39 | 12.59 | 2.36 | 0.024 | 0.024 | 0.2307 | 0.2094 | 0.5462 | 1.98 | 5.78 | -- | 5.65 | -- | 7.29 | -- | 29.73 | -- | 10.35 | -- | 0.5366 | 0.6521 | 0.5325 | -- | 76.98 | -- | 139.15 | -- | -- | -- |
| Medexus Pharmaceuticals Inc | 142.72m | 522.35k | 92.07m | 91.00 | 123.30 | 1.28 | 7.12 | 0.6451 | 0.023 | 0.023 | 4.77 | 2.22 | 0.7062 | 1.35 | 8.30 | 1,568,394.00 | 0.2585 | -3.71 | 0.4872 | -6.22 | 53.01 | 52.71 | 0.366 | -5.74 | 0.3763 | 1.24 | 0.2867 | -- | -4.18 | 14.31 | 1,150.00 | -- | 24.90 | -- |
| Charlotte's Web Holdings Inc | 67.51m | -29.73m | 102.03m | 112.00 | -- | 8.03 | -- | 1.51 | -0.1873 | -0.1873 | 0.4251 | 0.0797 | 0.4893 | 1.39 | 36.51 | 602,725.90 | -21.55 | -28.40 | -24.66 | -32.20 | 44.26 | 46.82 | -44.04 | -74.38 | 1.65 | -6.81 | 0.8408 | -- | -21.36 | -12.09 | -25.42 | -- | -23.86 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Dimensional Fund Advisors LPas of 08 Jan 2026 | 135.20k | 0.42% |
| Perritt Capital Management, Inc.as of 31 Oct 2025 | 125.00k | 0.39% |
| Dimensional Fund Advisors Ltd.as of 30 Nov 2025 | 9.27k | 0.03% |
| DFA Australia Ltd.as of 30 Nov 2025 | 5.43k | 0.02% |
| Goodwood, Inc.as of 30 Jun 2025 | 0.00 | 0.00% |
